October 19, 2016
FDA approves Roche’s cancer immunotherapy Tecentriq for metastatic NSCLC
FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
October 19, 2016
GW Pharmaceutical cancels trading shares on AIM on December 2, 1016, continues trading on NASDAQ
GW Pharmaceuticals plc has announced leaving AIM and canceling trading in London, to continue trading only on NASDAQ.
October 19, 2016
Advandec Oncotherapy’s Harley Street site planning permission granted
Advanced Oncotherapy , the developer of proton therapy systems for cancer treatment, has announced on Tuesday that planning permission for the Harley Street site was granted.
October 19, 2016
Keopsys group makes changes in Quantel’s Board
KEOPSYS Group holding company, acquired for € 5 million, 93.8% of the capital of EURODYNE, which holds 1,184,513 QUANTEL shares and 1,928,579 voting rights, representing 14.6% of the capital and 21.3% of the voting rights of QUANTEL.
October 19, 2016
Quantum Pharma names new CEO and makes other board changes
Quantum Pharma names new CEO and makes other board changes
@qp_group
October 13, 2016
Allergan’s BELKYRA Receives Marketing Authorisation In Sweden
Allergan announced that Sweden has received the Marketing Authorisation for BELKYRA (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA).
October 12, 2016
Ablynx, Merck further extend their collaboration on ion channel research, Ablynx gets €1M
Ablynx has extended for a second time its research collaboration with a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada, to develop and commercialise Nanobody candidates directed towards an undisclosed voltage gated ion channel.
October 11, 2016
FDA’s approval of NIcox’s cetirizine eye drop formulation triggers $35M in NIcox shares
The approval of the AC-170 NDA after December 1, 2016 would trigger a milestone payment of $10 million in Nicox shares to ex-Aciex shareholders or $35 million in Nicox shares if approval of the NDA is received before this date.
October 11, 2016
ABIVAX hostsR&D Day at its new laboratory in Montpellier
ABIVAX is hosting an R&D Day at the Company’s new collaborative laboratory with the French National Center for Scientific Research (CNRS) in Montpellier.
October 11, 2016
Biocartis’ Idylla technology could enhance molecular diagnostic testing
Biocartis Group NV, a Belgian innovative molecular diagnostics company has published a comparative study organised by AstraZeneca where 12 different KRAS mutation detecting technologies, including Next-Generation Sequencing (NGS) and quantitative Polymerase Chain Reaction (PCR), were compared for the detection of KRAS mutations in lung cancer, using blinded samples.